Skip to main content

Rheumatoid Arthritis

      EULAR Daily Recap: Day 4
      Dual seropositivity and shared epitopes in RA: friends or foes?

      Dual seropositivity, RF and/or anti-citrullinated prot

      Dr. John Cush RheumNow

      1 year 3 months ago
      Dual seropositivity and shared epitopes in RA: friends or foes? Dual seropositivity, RF and/or anti-citrullinated protein antibodies (ACPA) as well as shared epitope (SE) are known to be associated with poor prognosis and structural damage in RA. https://t.co/QcTHpgPV2Q https://t.co/TzueMr8M5T
      It is almost four years since EULAR published its definition of difficult-to-treat (D2T) rheumatoid arthritis (RA) (1). This marked a formal recognition of the group of patients who, despite the advances in pharmacological therapy for RA, remain symptomatic.
      EULAR 2024: New drugs for RA?

      Abiprubart is an Abatacept distant relative, targeting T cell activation through a differ

      Dr. John Cush RheumNow

      1 year 3 months ago
      EULAR 2024: New drugs for RA? Abiprubart is an Abatacept distant relative, targeting T cell activation through a different target/molecular interaction (CD40/CD154). https://t.co/3wAGjfCdcN https://t.co/2YK2OeIVZK
      EULAR Daily Recap: Day 3
      How many #autoantibodies
      Does one need in
      #rheumatoid #arthritis

      Need 4 citrullinated peptides
      Covers off
      97% of IgG

      Janet Pope Janetbirdope

      1 year 3 months ago
      How many #autoantibodies Does one need in #rheumatoid #arthritis Need 4 citrullinated peptides Covers off 97% of IgG CVP2 ACPAs #EULAR2024 @RheumNow @eular_org https://t.co/LNFGuFXGrC
      #EULAR2024 POS0467 - Periodontal disease related tot he development of #RA
      ACPA positive and negative pts.
      Tooth extract

      Bella Mehta bella_mehta

      1 year 3 months ago
      #EULAR2024 POS0467 - Periodontal disease related tot he development of #RA ACPA positive and negative pts. Tooth extraction in CCP positive pts was associated. Need tooth history in RA. @RheumNow https://t.co/b9Nb3cd0kd
      EULAR

      OP0041 (2024)
      COMPARISON OF b/tsDMARDs ABOUT NON-INFLAMMATORY PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS–ANSWE

      Peter Nash drpnash

      1 year 3 months ago
      EULAR OP0041 (2024) COMPARISON OF b/tsDMARDs ABOUT NON-INFLAMMATORY PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS–ANSWER LONGITUDINAL COHORT STUDY. 25% RA have significant non-inflammatory pain https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
      EULAR
      OP0092 (2024)
      INFECTIONS IN PATIENTS WITH RA TREATED WITH JAKi COMPARED TO bDMARDs: AN INTERNATIONAL COLLABORATI

      Peter Nash drpnash

      1 year 3 months ago
      EULAR OP0092 (2024) INFECTIONS IN PATIENTS WITH RA TREATED WITH JAKi COMPARED TO bDMARDs: AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY) TNF,OMA,JAK 7-10/100 pt.yr no signif diff except for zoster >30,000pts https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
      #EULAR2024 highlight from Prof Pitzalis & team- synovial phosphoproteome analysis in late-stage RA identifies signal

      Mrinalini Dey DrMiniDey

      1 year 3 months ago
      #EULAR2024 highlight from Prof Pitzalis & team- synovial phosphoproteome analysis in late-stage RA identifies signalling pathways assoc with pathotype & response to RTX & TOC Study highlights active signalling pathways assoc with pathotype & drug response OP0218 @RheumNow https://t.co/RZMSgj9T6k
      ×